Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modelling
Arthritis & Rheumatism Jan 24, 2018
Deakin CT, et al. - The target of this study was to illustrate the clinical improvement in juvenile dermatomyositis (JDM) patients treated with cyclophosphamide (CYC) and model efficacy of CYC compared to patients not treated with CYC. Findings demonstrated that CYC was efficacious and did not display any short-term side-effects. Researchers found improvements in skin, global and muscle disease.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
